Palmitoylethanolamide and luteolin vs no intervention
Generic quality of life measures · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found